MARINUS PHARMACEUTICALS, INC.
MRNS evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- ztalmy (Approved)
What it means
What to watch
Prepared research question
What matters most for MRNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
ztalmy (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate · 3 clinical trials for MARINUS PHARMACEUTICALS, INC..
Run MARINUS PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MARINUS PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is MARINUS PHARMACEUTICALS, INC.'s lead drug candidate?
MARINUS PHARMACEUTICALS, INC.'s most advanced tracked candidate is ztalmy (Approved) for Seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD).
Who is the CEO of MARINUS PHARMACEUTICALS, INC.?
Scott Braunstein, M.D. is the chief executive officer of MARINUS PHARMACEUTICALS, INC. (MRNS).
What therapeutic areas does MARINUS PHARMACEUTICALS, INC. focus on?
MARINUS PHARMACEUTICALS, INC. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.